{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:38:43Z","timestamp":1771785523566,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00345-016-1933-0","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T11:32:40Z","timestamp":1473939160000},"page":"729-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer"],"prefix":"10.1007","volume":"35","author":[{"suffix":"Jr.","given":"M. L.","family":"Blute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. J.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. M.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. F.","family":"Jarrard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"1933_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969\u2013974","journal-title":"JAMA"},{"key":"1933_CR2","doi-asserted-by":"publisher","first-page":"S21\u201325","DOI":"10.1097\/01.ju.0000088840.95085.2a","volume":"170","author":"MR Cooperberg","year":"2003","unstructured":"Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR (2003) CaPSURE: Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170:S21\u201325 (discussion S26\u201327)","journal-title":"J Urol"},{"key":"1933_CR3","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1200\/JCO.2011.34.9738","volume":"29","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: progress and promise. J Clin Oncol 29:3669\u20133676","journal-title":"J Clin Oncol"},{"key":"1933_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","volume":"61","author":"JI Epstein","year":"2012","unstructured":"Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61:1019\u20131024","journal-title":"Eur Urol"},{"key":"1933_CR5","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.juro.2008.11.107","volume":"181","author":"SL Conti","year":"2009","unstructured":"Conti SL, Dall\u2019era M, Fradet V, Cowan JE, Simko J, Carroll PR (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181:1628\u20131633 (discussion 1633\u20131624)","journal-title":"J Urol"},{"key":"1933_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.juro.2010.10.057","volume":"185","author":"SE Eggener","year":"2011","unstructured":"Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869\u2013875","journal-title":"J Urol"},{"key":"1933_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.juro.2013.09.034","volume":"191","author":"A Vellekoop","year":"2014","unstructured":"Vellekoop A, Loeb S, Folkvaljon Y, Stattin P (2014) Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol 191:350\u2013357","journal-title":"J Urol"},{"key":"1933_CR8","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1002\/cncr.28303","volume":"119","author":"M Truong","year":"2013","unstructured":"Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ et al (2013) Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer 119:3992\u20134002","journal-title":"Cancer"},{"key":"1933_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/jncimonographs\/lgs036","volume":"2012","author":"HB Carter","year":"2012","unstructured":"Carter HB (2012) Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr 2012:175\u2013183","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1933_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26:565\u2013574","journal-title":"Med Decis Making"},{"key":"1933_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1756287213495915","volume":"5","author":"KC Cary","year":"2013","unstructured":"Cary KC, Cooperberg MR (2013) Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol 5:318\u2013329","journal-title":"Ther Adv Urol"},{"key":"1933_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrurol.2015.159","volume":"12","author":"ML Blute","year":"2015","unstructured":"Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF (2015) Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol 12:435\u2013444","journal-title":"Nat Rev Urol"},{"key":"1933_CR13","unstructured":"Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE (2014) Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 67:569\u2013576"},{"key":"1933_CR14","doi-asserted-by":"publisher","first-page":"E494\u2013499","DOI":"10.1111\/j.1464-410X.2012.11182.x","volume":"110","author":"JJ Oh","year":"2012","unstructured":"Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE (2012) Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 110:E494\u2013499","journal-title":"BJU Int"},{"key":"1933_CR15","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","volume":"29","author":"JJ Tosoian","year":"2011","unstructured":"Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185\u20132190","journal-title":"J Clin Oncol"},{"key":"1933_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nrclinonc.2014.73","volume":"11","author":"L Klotz","year":"2014","unstructured":"Klotz L, Emberton M (2014) Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol 11:324\u2013334","journal-title":"Nat Rev Clin Oncol"},{"key":"1933_CR17","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1200\/JCO.2010.33.0134","volume":"29","author":"SP Porten","year":"2011","unstructured":"Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR (2011) Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 29:2795\u20132800","journal-title":"J Clin Oncol"},{"key":"1933_CR18","doi-asserted-by":"crossref","unstructured":"Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR (2014) Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int 114:18\u201324","DOI":"10.1111\/bju.12554"},{"key":"1933_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","volume":"185","author":"JM Whitson","year":"2011","unstructured":"Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185:1656\u20131660","journal-title":"J Urol"},{"key":"1933_CR20","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","volume":"28","author":"AE Ross","year":"2010","unstructured":"Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810\u20132816","journal-title":"J Clin Oncol"},{"key":"1933_CR21","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.5858\/arpa.2014-0219-SA","volume":"138","author":"MB Amin","year":"2014","unstructured":"Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L et al (2014) The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists and the Prostate Cancer Foundation. Arch Pathol Lab Med 138:1387\u20131405","journal-title":"Arch Pathol Lab Med"},{"key":"1933_CR22","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.juro.2011.12.082","volume":"187","author":"V Iremashvili","year":"2012","unstructured":"Iremashvili V, Soloway MS, Rosenberg DL, Manoharan M (2012) Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 187:1594\u20131599","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1933-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-016-1933-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1933-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T14:37:16Z","timestamp":1581950236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-016-1933-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["1933"],"URL":"https:\/\/doi.org\/10.1007\/s00345-016-1933-0","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]},"assertion":[{"value":"29 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Human research was performed under University Wisconsin and Johns Hopkins Internal Review Board approval and meets the criteria for ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}